BKG Pharma's Antibiotic Program provides drug candidates with a strong clinical potential, alone or in combination with traditional antibiotics, to optimize therapeutic treatment success.

Our candidates show high efficacy and specificity when tested against large panels of clinically relevant Gram-positive and Gram-negative isolates, including ESKAPE pathogens and other clinically relevant MDR strains. 

The effect comprises both a killing effect when used alone, and the effect of reversing microbial resistance to common antibiotics when used in combination at sub-MIC concentrations (synergism).

With promising preclinical data demonstrating a high level of safety and tolerance and excellent PK/PD properties, BKG Pharma is preparing to advance its first drug-candidates into clinical trials.